Mucinous adenocarcinoma of the ovary including metastatic ovarian cancer
Conditions
Interventions
Combination chemotherapy consisting of S-1+ Oxaliplatin (SOX)
Sponsors
Japan ovarian mucinous adenocarcinoma study group
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Patients with advanced (FIGO III-IV stage) or recurrent mucinous adenocarcinoma of the ovary with measurable lesions, including metastatic ovarian cancer 2.Performance status: 0-2 3.Age: 20 years and more than 20 years old 4.Patients who received no previous chemotherapy, or only one regimen not including TS-1 nor oxaliplatin. Treatment-free interval must be more than 4 weeks in patients with previous chemotherapy. 5.Patients possible to have tablet agent. 6.Patients without severe dysfunction of major organs 7.Patients possible to be alive over 3 months after treatment 8.Signed informed consent must be obtained
Exclusion criteria
Exclusion criteria: 1.Patients having fever over 38.0 2.Patients with infection or more than WBC:12,000/mm3 3.Patients with severe complications 4.Patients with double cancer 5.Patients with massive pleural effusion, ascites and pericardial fluid need to continuous drainage 6.Patients with severe paresthesia with functional disorder, or dysesthesia 7.Patients who cannot undergo treatment due to the past history of mental disorder or the central nerve disorder 8.Patients with brain metastasis 9.Patients with more than grade 3 diarrhea. More than grade 2 diarrhea in patients receiving colostomy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of adverse event Progression free survival Overall survival | — |
Countries
Japan
Contacts
Public ContactMuneaki Shimada
Faculty of Medicine, Tottori University Department of Obstetrics and Gynecology
Outcome results
None listed